Medtronic unveils results from first-in-human study for EV ICD systems
Category: #health  By Saipriya Iyer  Date: 2019-05-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Medtronic unveils results from first-in-human study for EV ICD systems

Medtronic plc has reportedly unveiled the results from a test study of its investigational extravascular ICD system, where a lead is positioned outside of the heart and veins to provide anti-tachycardia pacing therapy and lifesaving defibrillations in one system, using a device as big as conventional, transvenous ICDs.
Reportedly, findings from the study were exhibited over a late-breaking session at the 40th Heart Rhythm Session.

Sources claimed that the pilot study, which denotes the first-in-human long-term use of investigational, first-generation system, exhibits that this system could be implanted without any major complications, and can effectively sense, defibrillate, and pace the heart.

Reportedly, the pilot study was conducted on 21 patients across four sites in Australia and New Zealand. Patients were assessed at implant, 2 weeks, 4 to 6 weeks, and 3 months post device’s implantation, and continue to be followed. As per investigators, the defibrillation tests were conducted on 19 patients, at the time of implant. The system effectively terminated induced ventricular arrhythmias in 17 patients, which is steady with previous clinical trials of existing ICDs. Moreover, the pacing capture was accomplished in over 95 percent of study patients. Among which, one individual suffered ventricular tachycardia outside the hospital premises, which was effectively diagnosed and treated through the EV ICD system, cited investigators.

For the record, through EV ICD systems, Medtronic aims to deliver the benefits of conventional, transvenous ICDs comprising anti-tachycardia pacing to tackle arrhythmias; lifesaving defibrillation therapy; post-shock pacing; and provisional back-up, bradycardia pacing to treat unusually slow heart rates. The EV ICD device is fixed in the left mid-axillary area underneath the left armpit, while the lead is positioned below the sternum or breastbone.

The EV ICD system is investigational globally and therefore, not permitted for sale or distribution, reported sources.

Source Credit: https://www.globenewswire.com/news-release/2019/05/11/1822165/0/en/Medtronic-Reveals-Results-of-First-In-Human-Study-for-Investigational-Extravascular-ICD-System.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

New Medtronic Micra AV pacemaker receives approval from the U.S. FDA
New Medtronic Micra AV pacemaker receives approval from the U.S. FDA
By Saipriya Iyer

Medtronic plc, a renowned US-based medical device company, reportedly announced that its Micra AV pacemaker has received approval from the U.S. FDA. The Medtronic Micra AV is the world’s smallest pacemaker with A...

Health Canada grants two DIN to new Tetra Bio-pharma OTC products
Health Canada grants two DIN to new Tetra Bio-pharma OTC products
By Saipriya Iyer

Tetra Bio-pharma, a renowned Canadian biopharmaceutical company, reportedly announced that Health Canada, the regulatory health authority of Canada, has granted two new DIN (Drug Identification Numbers) for the first O...

Digital River & Magento team-up to create customized commerce solution
Digital River & Magento team-up to create customized commerce solution
By Saipriya Iyer

Digital River, a renowned global ecommerce facilitator for well-known and fast-growing brands, has reportedly signed a new strategic partnership deal with Magento, a leading provider of commerce innovations to retailer...